The FDA’s 2027 budget proposal lays out regulatory reforms aimed at expediting development and review, including making the rare pediatric disease priority review voucher program permanent. If implemented, the plan would increase the FDA’s budget by more than $200 million in 2027 and create more “predictability for sponsors,” according to the budget document. The proposal also includes a new “clinical trial notification pathway” intended as an alternative to the current Investigational New Drug (IND) process, which the document characterizes as burdensome. The broader package is framed as shifting the agency “from a reactionary system to a proactive system,” with additional emphasis on national security and “radical transparency.” The rare pediatric voucher program was previously renewed intermittently, with a gap in 2024 when Congress did not reauthorize it, and it was restarted in 2025. The budget proposal’s permanence would reduce the risk of future interruptions. For biotech, the proposal is significant because it could change timelines and planning assumptions for rare disease sponsors trying to optimize regulatory strategy and trial entry in the U.S.